Jobs / United States / Novartis Pharmaceuticals Corporation
Director, Translational Medicine Expert (Neurodegeneration)
Novartis Pharmaceuticals Corporation · 🇺🇸 Cambridge (USA)
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Novartis Pharmaceuticals Corporation paid sponsored hires in similar roles1 certified filing for “Expert Science & Technology” (Biochemists and Biophysicists) in MA: $122k–$122k, median $122k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Novartis Pharmaceuticals Corporation
The US Department of Labor certified 75 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Novartis Pharmaceuticals Corporation →
About the role
Job Description Summary #LI-Hybrid Internal Title: Director Location: Cambridge, MA, USA The Director, Translational Medicine Expert (Neurodegeneration) will lead the end to end translational strategy for neurodegenerative programs, bridging preclinical research to early clinical development (Phase 1–2). This role is accountable for biomarker strategy, clinical endpoint selection, and early phase trial design, enabling efficient, data driven decision-making through key development milestones (e.g., Transition Decision Points) and ensuring competitive differentiation of neuromuscular assets. In addition, he/she oversees the planning, execution, and interpretation of clinical trials research, data collection activities and clinical operations. Establishes and approves scientific methods for design and implementation of clinical protocols, data collection systems and final reports. Support new and ongoing clinical research and clinical trials and ensure efficient and timely processing of confidentiality agreements and clinical agreements Job Description Key Responsibilities: 1. Translational Strategy & Program Leadership • • Define and execute integrated translational strategies across neurodegeneration programs • Lead translational components from preclinical → Phase 1/2 clinical studies • Drive program progression through key decision gates (e.g., IND, TDP, IDPA) • Ensure strong mechanistic linkage between target biology, biomarkers, and clinical endpoints 2. Biomarker & Endpoint Leadership • • Collaborate with Biomarker Development colleagues toward development and validation of: • Molecular biomarkers (tissue, blood, CSF where applicable) • Functional endpoints (strength, mobility, disease-specific measures) • Patient-reported outcomes (PROs) • Establishing quantitative biomarkers to support: • Target engagement • Disease modification • Dose selection and PoC decisions • Integrate biomarker strategy into clinical protocols and operational plans • Drive early biomarker de‑risking , a key priority in neuromuscular programs 3. Early Clinical Development (Phase 1/2) • • Co‑lead design and execution of early clinical studies • Define: • Dose escalation strategy • Exposure–response framework • Translational endpoints (biopsy, imaging, functional) • Ensure TM leadership within Clinical Trial Teams (CTTs) for: • Trial design • Execution oversight • Data interpretation and decision-making 4. Cross-Functional Leadership • • Serve as core Translational Medicine representative within global project teams • Partner closely with: • Clinical Development • Biomarker Development • Clinical Pharmacology (PKS) • Preclinical Safety (PCS) • Regulatory • Drive alignment between research, TM, and development organizations 5. External Scientific Leadership • • Build and lead collaborations with: • Academic KOLs • Patient advocacy groups (critical in rare neuromuscular disease) • Technology partners (imaging, omics platforms) • Contribute to scientific strategy and external positioning of programs 6. Patient-Centered Development • • Integrate the patient voice into translational and clinical strategies • Advance: • Meaningful functional endpoints • Patient-relevant outcome measures • Innovative trial approaches (e.g., decentralized models where feasible) 7. Portfolio Contribution & Strategic Input • • Contribute to: • Asset prioritization and portfolio strategy • Competitive differentiation strategy (e.g., vs RNA or gene therapy competitors) • Provide scientific input to: • Business development / due diligence • Indication expansion strategies Essential Requirements: · MD, neurologists, clinical training in neurodegenerative diseases · Experience in translational medicine, early clinical devel